Advertisement

Psychopharmacology

, Volume 106, Supplement 1, pp S43–S45 | Cite as

MAOIs to RIMAs in anaesthesia — a literature review

  • S. Hill
  • K. Yau
  • J. Whitwam
Section I RIMA: Pharmacology, Biochemistry And Interactions Mini-Paper

Abstract

Monoamine oxidase inhibitors (MAOIs) are widely accepted as effective antidepressants. Unfortunately their use has been limited by their capacity to potentiate dietary tyramine (the so called “cheese effect”) and their interaction with other drugs. The latter poses a particular problem for patients undergoing anaesthesia. Traditional advice has been to stop MAOI therapy 2 weeks prior to anaesthesia. With the advent of reversible, specific inhibitors of MAO-A (RIMAs) there is less potential for dietary and drug interaction. While experience with these newer drugs is limited so far, this review suggests that combination of modern anaesthetic techniques and newer, specific reversible MAOIs should allow safe anaesthesia with maintenance of antidepressant therapy.

Key words

Monoamine oxidase inhibitor RIMA Anaesthesia Opiates Moclobemide 

References

  1. Amrein R, Allen SR, Vranesic D, Stabl M (1988) Antidepressant drug therapy: associated risks. J Neural Transm [suppl] 26:73–86Google Scholar
  2. Bazire S (1987) MAOIs and narcotic analgesics (letter). Br J Psychiatry 151:701–710Google Scholar
  3. Bleaden FA, Czekanska G (1960) New drugs for depression. BMJ [1]:200Google Scholar
  4. Boden R, Botting R, Coulson P, Spanswick G (1984) Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice. Br J Pharmacol 82:151–154Google Scholar
  5. Bodley PO, Halwax K, Potts L (1969) Low serum pseudocholinesterase levels complicating treatment with phenelzine. BMJ 3:510–512Google Scholar
  6. El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R (1985) Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anaesth Analg 64:592–596Google Scholar
  7. Jounela AJ, Mattila MJ, Knoll J (1977) Interaction of selective inhibitors of monoamine oxidase with pethidine in rabbits. Biochemical Pharmacology, vol 26. Pergamon Press, Oxford, pp 806–808Google Scholar
  8. Loveless AH, Maxwell DR (1965) A comparison of the effects of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol 25:158–170Google Scholar
  9. Palmer H (1960) Potentiation of pethidine. BMJ 2:944Google Scholar
  10. Penn RG, Rogers KJ (1971) Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with a monoamine oxidase inhibitor. Br J Pharmacol 42:485–492Google Scholar
  11. Powell H (1990) Use of alfentanil in a patient receiving monoamine oxidase inhibitor therapy. Br J Anaesth 64:528Google Scholar
  12. Remick RA, Jewesson P, Ford RWJ (1987) Monoamine oxidase inhibitors in general anesthesia: a reevaluation. Convulsive therapy 3[3]:196–203Google Scholar
  13. Rivers N, Horner B (1970) Possible lethal reaction between nardil and dextromethorphan. Can Med Assoc J 103:85Google Scholar
  14. Shamsie SJ, Barriga C (1971) The hazards of use of monoamine oxidase inhibitors in disturbed adolescents. Can Med Assoc J 104:715Google Scholar
  15. Stack CG, Rogers P, Linter SPK (1988) Monoamine oxidase inhibitors and anaesthesia. Br J Anaesth 60:222–227Google Scholar
  16. Stockley I (1981) Chap 16. Monoamine oxidase inhibitor drug interactions. In: Drug interactions. Blackwell, Oxford, pp 365–366Google Scholar
  17. Wells DG, Bjorksten AR (1989) Monoamine oxidase inhibitors revisited. Can J Anaesth 36:64–74Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • S. Hill
    • 1
  • K. Yau
    • 2
  • J. Whitwam
    • 2
  1. 1.Roche Products Ltd, CNS GroupWelwyn Garden CityUK
  2. 2.Department of Anaesthetics, Royal Postgraduate Medical SchoolHammersmith HospitalLondonUK

Personalised recommendations